Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Budget Bill Makes End Run Around Medicare Payment Policy For Omidria, Amyvid

Executive Summary

Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.

You may also be interested in...



No Deal: Omnibus Spending Bill Moves Without Part D Discount Relief

Biopharma lobbying to include provision to reduce the 70% discount on brands in the budget bill runs out of time, leaving industry evaluating other possible legislative vehicles.

FDA OK's Omeros cataract surgery drug Omidria; eyes on pricing

With the FDA's approval in hand for Omidria (phenylephrine and ketorolac injection) for use during cataract surgery or intraocular lens replacement (ILR), all eyes are now on the drug's pricing and launch, which is anticipated late summer or early fall.

CMS’ Amyvid Final NCD Clarifies Trial Outcomes Goals

Agency’s final national coverage determination for beta amyloid positron emission tomography in diagnosing dementia confirms stance the diagnostic will be covered only in trial setting for Medicare, but may offer a little more flexibility in trial design.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel